| (210) | Number of the EPO application | 23154663 |
| (220) | Filing date of the EPO application | 2019.11.13 |
| (80) | EPO patent specification publication (B) | EPB nr. 13/2026, 2026.03.25 |
| (110) | EPO patent number | 4218754 |
| (21) | Number of the application | e 2024 0329 |
| (71) | Name(s) of applicant(s), code of the country | VERTEX PHARMACEUTICALS INCORPORATED, US; |
| (72) | Name(s) of inventor(s), code of the country | ALTSHULER David M., US;
ANDERSON Corey Don, US;
CHEN Weichao George, US;
CLEMENS Jeremy J, US;
CLEVELAND Thomas, US;
COON Timothy Richard, US;
FRIEMAN Bryan, US;
GROOTENHUIS Peter, US;
HADIDA RUAH Sara Sabina, US;
HARE Brian J., US;
KEWALRAMANI Reshma, US;
MCCARTNEY Jason, US;
MILLER Mark Thomas, US;
PARASELLI Prasuna, US;
PIERRE Fabrice, US;
ROBERTSON Sarah M., US;
SOSNAY Patrick R., US;
SWIFT Sara E., US;
ZHOU Jinglan, US;
BOREK Bartlomiej, US;
VAN GOOR Fredrick, US;
YOUNG Tim, US; |
| (73) | Name(s) of owner(s), code of the country | VERTEX PHARMACEUTICALS INCORPORATED, US; |
| (54) | Title of the invention | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/404 (2006.01.01); A61K 45/06 (2006.01.01); A61K 31/47 (2006.01.01); A61P 11/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2024.04.30 |
| (30) | Priority | 201862767202 P, 2018.11.14, US |